from
S&P Credit Research1414 word report
published Aug 13, 2008
Price
$175.00 available for immediate download
Report Overview
Search Inside
About
S&P Credit Research
| Abstract: | On Aug. 13, 2008, Standard&Poor's Ratings Services affirmed its ratings on Woonsocket, R.I.-based CVS Caremark Corp, including its 'BBB+' corporate credit rating. The affirmation follows the announcement that CVS Caremark will acquire Longs Drug Stores for a total purchase price of $2.9 billion, including the assumption of net debt. The acquisition will be funded by a $1.5 billion bridge loan facility, together with borrowings under its commercial paper (CP) program and cash. The outlook is stable The rating affirmation is based on CVS Caremark's track record in integrating acquired retail stores, its strong cash flow generation and the expected debt reduction to restore credit measures to levels more appropriate for the rating. Although the transaction results in a
|
| Brief Excerpt: | RESEARCH Ratings Definitions Research Update: CVS Caremark Corp. '###+' Corporate Credit Rating Affirmed; Outlook Stable Publication date: 13-Aug-2008 Primary Credit Analyst: Ana Lai, CFA, New York (1) 212-438-7895; ana_lai@standardandpoors.com...
|
| Report Type: | Research Update
|
| Ticker: | CVS
|
| Issuer: | CVS Caremark Corp.
|
| GICS: | Drug Retail (30101010)
|
| Sector: | Commercial MBS, Corporations, Financial Institutions, Global Issuers, Health Care, Retail, Structured Finance
|
| Country: | United States
|
| Region: | United States
|
| Free Sample: |
Click Here to Download
|
| Format: | | HTML |  |
|
S&P Credit Research provides analysis on issuers and debt obligations of corporations, states and municipalities, financial institutions, insurance companies and sovereign governments. S&P also offers insight into the credit risk of structured finance deals, providing an independent view of credit risk associated with a growing array of debt-securitized instruments.
Also from S&P Credit Research
- CVS Caremark Corp. $400.00
Largest position in the high-growth chain drug retail industry based on sales and units; Leading position in the PBM industry; Solid growth prospects; and Strong cash flow and good liquidity. Participates in a highly competitive industry; History ...
- Summary: CVS Caremark Corp. $175.00
The ratings on CVS Caremark Corp. reflect the company's solid position in the favorably regarded drugstore industry, leading position as a pharmacy benefit management (PBM) company, diverse cash flow stream, and generally good operating performance. ...
- CVS Caremark Corp. 'BBB+' Corporate Credit Rating Affirmed; Outlook Revised To Negative $100.00
CVS Caremark's pharmacy benefits manager (PBM) lost more contracts than expected and segment profits will likely decline in 2010. Leverage could rise to 3.0x in 2010. We are changing the outlook to negative from stable and affirming the 'BBB+' ...
- Research Update: CVS Caremark Corp. Outlook Revised To Negative; 'BBB+' Corporate Credit Rating Affirmed $175.00
CVS Caremark's pharmacy benefits manager (PBM) lost more contracts than expected and segment profits will likely decline in 2010. Leverage could rise to 3.0x in 2010. We are changing the outlook to negative from stable and affirming the 'BBB+' ...
- Summary: CVS Caremark Corp. $175.00
The ratings on CVS Caremark Corp. reflect its solid position in the favorably regarded drugstore industry, leading position as a pharmacy benefit manager (PBM), diverse cash flow stream, and generally good operating performance. These strengths ...
- CVS Caremark Corp. $400.00
Largest position in the high-growth chain drug retail industry based on sales and units; Leading position in the pharmacy benefit management (PBM) industry; Solid growth prospects; and Strong cash flow and good liquidity. Participates in a ...
- Summary: CVS Caremark Corp. $175.00
The ratings on CVS Caremark Corp. reflect its solid position in the favorably regarded drugstore industry, leading position as a pharmacy benefit manager (PBM), diverse cash flow stream, and generally good operating performance. These strengths ...
- Bulletin: Competing Offer For Longs Drug Stores Has No Effect On CVS/Caremark Ratings $100.00
NEW YORK (Standard&Poor's) Sept. 15, 2008—Standard&Poor's Ratings Services said today that Walgreen Co.'s (A+/Watch Neg/--) competing higher offer to purchase Longs Drug Stores Corp. (not rated) in a transaction valued at about $3.0 billion ...
